I think I would frame the central debate as the question of how far we should be treating the percentage stenosis versus treating an individual patient’s risk. There is broad agreement on whether, when a patient has a symptomatic significant carotid stenosis, that revascularization can help improve these patients when selected appropriately. I think the bigger question and the more challenging question is, what do we do with those patients who do not fit into this traditional criteria and norm? So, for example, if you have asymptomatic stenosis or somebody with a modest stenosis or somebody with a modest stenosis and concerning plaque features...
I think I would frame the central debate as the question of how far we should be treating the percentage stenosis versus treating an individual patient’s risk. There is broad agreement on whether, when a patient has a symptomatic significant carotid stenosis, that revascularization can help improve these patients when selected appropriately. I think the bigger question and the more challenging question is, what do we do with those patients who do not fit into this traditional criteria and norm? So, for example, if you have asymptomatic stenosis or somebody with a modest stenosis or somebody with a modest stenosis and concerning plaque features. So, those are the group of patients that we are more worried about and where, you know, the kind of decision varies. So, one school of thought proposes that now with advanced modern medicine, we have excellent medical management, such as we have lipid-lowering therapies which are far better, antithrombotics, blood pressure management, such that we may not need to intervene in all of these asymptomatic patients so as to see a clinically meaningful benefit. The other perspective is that we should not be treating the stenosis alone but we need to be looking at other concerning plaque features such as plaque morphology, unstable plaque, ulceration, intraplaque hemorrhage, and so on. So, my own take-home message is that precision medicine does not mean that we need to intervene on every plaque that seems concerning, but also we should not be so ignorant as to miss out on any of these dangerous plaques. Evidence linking the lesion to the actual stroke and understanding whether the lesion that we are seeing on the imaging is actually connected to the stroke that we’re seeing on the patient – for now, we do not have any established guidelines, so we just continue to do what we’ve been doing, but I think in the future we need to look at prospective registries, collaborative comparative data, so as to try and understand which of these patients would additionally benefit from some kind of intervention.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.